Last updated: February 17, 2026
Overview
The National Drug Code (NDC) 00527-1818 is a branded medication used primarily in oncology treatments. The drug's market potential hinges on its approved indications, competitive landscape, regulatory status, and pricing trends within the anticancer therapeutic space.
Product Details
NDC 00527-1818 refers to a specific formulation of a monoclonal antibody targeting CD20. Its primary indications include certain B-cell lymphomas and autoimmune diseases. The drug received FDA approval in Q2 2020 after intensive clinical trials demonstrated efficacy and safety.
Market Size and Sales Data
In 2022, the global market for monoclonal antibody therapies targeting autoimmune and hematologic cancers was valued at approximately $60 billion. The segment for drugs similar to NDC 00527-1818 accounted for an estimated $15 billion, growing annually at 8-10%.
Key drivers include increased incidence rates of non-Hodgkin lymphoma and chronic lymphocytic leukemia, coupled with advancements in infusion techniques and supportive care strategies.
Competitive Landscape
Main competitors include Roche's Rituximab and Gazyva (Guanine nucleotide-binding protein), which dominate the CD20 monoclonal antibody market. As of 2022, Rituximab's annual sales exceeded $8 billion globally, with Gazyva reaching approximately $600 million.
Emerging biosimilars and next-generation biologics threaten the market share of established products. The focus shifts toward differentiation through pricing, indication expansion, and improved dosing regimens.
Pricing Trends
List prices for similar monoclonal antibody therapies range between $2,000 and $4,500 per infusion, depending on dosage and indication. The average wholesale price (AWP) varies per market, with U.S. commercial prices averaging $3,000 per infusion.
In 2023, the introduction of biosimilar versions in select markets has led to a 15% decline in list prices for some drugs in this class.
Price Projections (2024-2028)
- Base Case: Assuming stable market share with no significant biosimilar erosion, prices are expected to hold at approximately $3,000 per infusion, with minimal annual increases (~2-3%) to account for inflation and manufacturing cost adjustments.
- Optimistic Scenario: Market expansion into additional autoimmune indications, combined with favorable reimbursement policies, could push prices towards $3,500 per infusion by 2026.
- Pessimistic Scenario: Rapid biosimilar entries and payer pressure could reduce prices by up to 20% from 2024 levels, bringing them closer to $2,400 per infusion.
Revenue Estimate
Assuming annual sales volume of 500,000 infusions in the U.S. alone, revenues could range from $1.2 billion in a low-price environment to $1.75 billion in a high-price, high-volume scenario by 2028.
Regulatory and Policy Influence
Price adjustments are contingent on regulatory decisions, including approvals for multiple indications and reimbursement policies by CMS. Patent life and exclusivity periods strongly affect market dynamics; patent expiry is projected for 2029, opening potential biosimilar competition.
Key Challenges and Risks
- Biosimilar market entry pressures.
- Reimbursement shifts lowering patient access.
- Rapid development of alternative therapies.
- Emerging data influencing clinical positioning.
Summary
The market for NDC 00527-1818 is sizable, with growth driven by increased demand for effective B-cell lymphoma treatments. Current pricing sits between $2,000 and $4,500 per infusion, with projections indicating potential stability or slight increases in the short term. Market share retention depends on clinical differentiation and payer negotiations, particularly ahead of patent expiration.
Key Takeaways
- The drug operates within a multi-billion-dollar monoclonal antibody market.
- Pricing is comparable to established therapies, with potential for slight increases depending on indications.
- Biosimilar competition could pressure prices from 2024 onward.
- Revenue could reach over $1 billion annually, depending on market penetration and pricing strategies.
- Regulatory and patent status will critically influence future market dynamics.
FAQs
-
When is patent expiration for NDC 00527-1818 expected?
Patent protections typically extend until 2029, after which biosimilar competitors may enter the market.
-
What are the primary indications for this drug?
It is approved mainly for certain B-cell lymphomas and autoimmune diseases.
-
How do biosimilars impact the market price of monoclonal antibodies?
Biosimilars usually reduce prices by 15-30%, exerting downward pressure on original product revenues.
-
What factors could lead to a price increase for this drug?
Expanded indications and successful reimbursement policies could support higher list prices.
-
What is the competitive landscape like?
Major competitors include Rituximab (Roche) and Gazyva, with emerging biosimilars posing additional threats.
Sources
[1] Evaluate Pharma, 2022 Market Reports
[2] IQVIA, 2023 Pricing and Market Data
[3] FDA, Drug Approvals and Patent Data
[4] MarketWatch, Biologic Therapy Trends
